Sight Diagnostics IPO

sightdx.com/en-usHealthcare / Medical Devices

Sight Diagnostics is an Israeli medical devices startup that’s using AI technology to speed up blood testing. Its mission is to change the way blood testing is done by providing fast, convenient and accurate diagnostics in a compact platform designed for use in any clinical setting, overseen by CLIA certified lab. Developed over almost a decade of research, its technology combines the latest innovations in blood sample preparation, optics, chemistry, biology, physics and computer science. Its first product, Parasight™, has diagnosed malaria in nearly 1 million tests across 24 countries. Sight OLO®, their latest blood analyzer, digitizes blood with only 2 drops of a finger prick or venous sample and provides lab-grade CBC results in minutes.

Buy or sell Sight Diagnostics stock Learn more about Sight Diagnostics stock

Learn more about Sight Diagnostics

Is Sight Diagnostics a publicly traded company?

Sight Diagnostics is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

Will Sight Diagnostics go IPO?

Sight Diagnostics has not yet filed for an IPO. However, it's important to note that IPOs are not the sole avenue for a private company to transition to public trading. Private companies can also go public through alternative methods such as but limited to Special Purpose Acquisition Companies (SPACs), direct listings, or through mergers and acquisitions. Find out which companies are eyeing an IPO on our Tech IPO Calendar 2024.

What is Sight Diagnostics's IPO price?

The IPO price for Sight Diagnostics will be known only if it becomes public. However, you may access the "Price At Last Round" and the "Implied EV" for publicly traded comparable companies with Forge Data.

Can you invest in Sight Diagnostics pre-IPO?

Sight Diagnostics is privately held company and is not publicly traded, therefor investing in Sight Diagnostics pre-IPO is only available to accredited investors. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to invest in private companies before their potential IPO. If you are not an accredited investor, discover how to begin the the process to potentially qualify for new investment opportunities.

What is the value of my Sight Diagnostics shares?

To determine the value of your Sight Diagnostics shares, create a free account to gain access to Forge’s platform. Forge Markets contains pricing information for hundreds of pre-IPO companies. A Private Market Specialist will also be available to assist you with any inquiries related to your Sight Diagnostics shares. You can also learn more about how to sell your private shares before getting started.

Can you sell Sight Diagnostics before it goes public?

Yes, you can seek to sell shares in Sight Diagnostics while it remains private. If you are considering selling, you can register today for free to get started. Once registered, a Private Market Specialist will guide you through any questions you might have. You may also continue to browse through our resources to help you understand the implications and procedures involved in selling your private market shares.

When was Sight Diagnostics founded?

Sight Diagnostics was founded in 2012.

Who are Sight Diagnostics's major investors?

Koch Disruptive Technologies

OurCrowd

BridgeOne Capital China

Longliv Ventures

Microtech Ventures

ForMED Ventures

Emery Capital

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.